TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

TPOXX® Antiviral Treatment (Tecovirimat)

Antivirals for systemic use
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency: "TPOXX® Antiviral Treatment (Tecovirimat)". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthoritySecretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3.1Bids / Report
61% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 134 active published awards; 82 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthoritySecretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published3 Nov 2022, 17:23 GMT
Last source update3 Nov 2022, 17:23 GMT
Recurring procurementNot published
ClassificationAntivirals for systemic use
Delivery area
UK
OCIDocds-h6vhtk-037efd
What is being bought
The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK.
What changed
From the official release history
  1. Status changed to complete
    3 Nov 2022, 17:23 GMT
  2. Official notice release published
    3 Nov 2022, 17:23 GMT
  3. Buyer information updated
    3 Nov 2022, 17:23 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    Supply of Tecovirimat antiviral treatment
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    3 Nov 2022, 17:23 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 28 Jul 2022, 00:00 BST · Not published
Commercial outcome and competition
Awards
MERIDIAN MEDICAL TECHNOLOGIES LIMITED
Not published · Not published · active
Contracts
Contract
Not published · signed 28 Jul 2022, 00:00 BST · active
Bid statistics
bids: 1 (lot 1)
highestValidBidValue: 1 (lot 1)
lowestValidBidValue: 1 (lot 1)
Buyer and organisations in this procedure

Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency

Contracting authority GB-FTS-34582
View buyer profile

  • Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
    buyer

    Nobel House, 17 Smith Square, London, UKI32, SW1P 3JR
    Simeon.Hadebe@dhsc.gov.uk

  • MERIDIAN MEDICAL TECHNOLOGIES LIMITED
    supplier

    NI020416
    Forsyth House, Cromac Square, Belfast, Co. Antrim, BT2 8LA, Belfast, UKN0, BT2 8LA

  • The High Court
    reviewBody

    Strand, London, WC2A 2LL
    generaloffice@administrativecourtoffice.justice.gov.uk
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleNegotiated procedure without a notice:<br/><br/>Regulation 32(2)(b)(ii)<br/><br/>This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of monkeypox in the UK.<br/><br/>The procurement was initiated on the basis that Regulation 32(2)(b)(ii) was applicable in the circumstances that prevailed. This permits the use of a direct award where competition is absent for technical reasons. That is the situation that applies here and as a result a competitive procurement exercise could not have been conducted.<br/><br/>The monkeypox virus belongs to a family of viruses called orthopox viruses. The drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. There was no reasonable alternative or substitute available to the authority. This antiviral is the only product with authorisation from the MHRA for the treatment of monkeypox and Meridian Medical Technologies has exclusive right to supply the product to the UK. Therefore, this was the only option available within the market for the UK to procure an effective treatment against the current monkeypox outbreak.